SETBP1 in Myeloid Malignancies—Putting Breadcrumbs Together in Rare, Uncommon, and Common Pediatric Cases

CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(01): 092-094
DOI: 10.1055/s-0043-1769491

Letter to the Editor

Autor*innen

Aroonima Misra^*

¹Scientist-C, Indian Council of Medical Research (ICMR)-National Institute of Pathology, New Delhi, India
Bhavika Rishi^*

¹Scientist-C, Indian Council of Medical Research (ICMR)-National Institute of Pathology, New Delhi, India
Srilatha Bajaj

²Department of Pediatrics, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi, India
Sumita Saluja

³Department of Laboratory Hematology, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi, India
Amitabh Singh

⁴Department of Pediatrics, Division of Pediatric Hematology/Oncology, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, New Delhi, India

References
1 Shiba N, Ohki K, Park MJ. et al. SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Br J Haematol 2014; 164 (01) 156-159
2 Carratt SA, Braun TP, Coblentz C. et al. Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia. Leukemia 2021; 35 (12) 3594-3599
3 Locatelli F, Niemeyer CM. How I treat juvenile myelomonocytic leukemia. Blood 2015; 125 (07) 1083-1090
4 Piazza R, Magistroni V, Redaelli S. et al. SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub. Nat Commun 2018; 9 (01) 2192
5 Alfayez M, Issa GC, Patel KP. et al. The clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia 2021; 35 (03) 691-700